Share this article:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • NewsVine
  • StumbleUpon
  • Twitter

TFN Reader Grapevine: There’s Something about Viral Genetics, Inc. (VRAL)

Today's Financial News - Posted August 25, 2009

Recent activity surrounding biotech penny stock Viral Genetics, Inc. (OTC:VRAL) indicates this company could be ready for a boost

by J. Christoph Amberger

Baltimore, MD — TFN: TFN eNews reader Cliff X. filed the following with us this afternoon:

“Viral Genetics, Inc. (OTC:VRAL) is a small company that develops and commercializes a series of proteins based primarily on thymus nuclear protein (TNP). These relate to combatting infectious diseases, such as HIV/AIDS, other autoimmune conditions and immunological deficiency.

“Rumor has it that they are planning something big – heard about them filing with the FDA re: investigatory new drug filing within the month.

“Right now, it’s just speculation, but apparently others may know more than me, as the stock started flying today around mid-afternoon. I was lucky enough to get into it at $0.495. Maybe your other members would be interested.”

I bet they are, Cliff!


Next Article: TFN eNews 08/25/2009: Could this tiny miner become a “most important global player”

3 Responses to “TFN Reader Grapevine: There’s Something about Viral Genetics, Inc. (VRAL)”

  • Daniel Dalh Says:

    I saw this one pop up on my radar screens this afternoon, def. going to load up here because if it starts swinging upwards again, this time it will likely break through the previous high $0.129.

  • Mike Says:

    VRAL………. I’ve been following Viral Genetics Inc. for a while now. This is a modern day Cinderella story at its best, the one of hundreds of unknown biotech penny stocks, for now. This is a company with the clinically proven treatment for highly infectious diseases, specifically AIDS. With overseas success in HUMAN trials.
    Their management team is outstanding and are financially secure enough for the FDA process and all its stages. With the recent attention the stock has been receiving it’s fair to say that the rumor mills are churning and something is definitely brewing. The fundamentals and potential have not been built into this stock yet but are starting to.
    I have no doubt in my mind that VRAL will be trading shoulder to shoulder with the likes of AMGN , JNJ and GENZ when they complete the FDA process, which will get fast tracked due to proven results and human urgency. There are lives to be saved which means money to be made with VRAL and the eyes of the wise are beginning to open.

  • squirrelfollower Says:

    i fond the information from your website, and even though it was a farse, i still made great money from it. i wouldn’t have made as much as i did if I didn’t see it here first. thanks for another double digit gain!

Your comments are welcome